AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 DEC 3 - (NewsRx.com & NewsRx.net) -- Targeted Genetics Corporation (TGEN) announced the issuance of an additional patent related to its adeno-associated virus (AAV) vector production technology.
U.S. patent #9,180,114, titled "Amplifiable Adeno-Associated Virus (AAV) Packaging Cassettes for the Production of Recombinant AAV Vectors," expands Targeted Genetics' production systems used to manufacture AAV vectors.
Targeted Genetics' leading gene delivery vehicle, AAV, is used to deliver a gene of interest into cells of the patient to impact disease. Targeted Genetics uses AAV technology for its AIDS vaccine, cystic fibrosis, and arthritis product candidates.
The patent describes Targeted Genetics' AAV production process that utilizes a small, human DNA sequence, P1. AAV vector production processes require the expression of AAV rep and cap genes.
In this patented process, the human P1 segment is linked to the AAV rep and cap genes in order to drive their expression for the purposes of AAV vector production containing the gene of interest. The technology in this patent demonstrates that this amplified rep and cap expression results in high titer AAV vector ...
Source: HighBeam Research, Patent expands adeno-associated virus manufacturing processes and...